Notes: Feb. 13, 2017 -- The business combination of Signal Genetics, Inc. (SGNL) and Miragen Therapeutics, Inc. has become effective today, February 13, 2017. Signal Genetics, Inc. (SGNL) will undergo a name, symbol, and CUSIP change effective Tuesday, February 14, 2017. <p> November 7, 2016 -- Signal Genetics, Inc. (SGNL) will effect a one for fifteen (1-15) reverse split of its common stock. The CUSIP number will change to 826640203. <p> 10/31/2016 -- Signal Genetics, Inc. (Nasdaq: SGNL) and Miragen Therapeutics, Inc. (miRagen), a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of miRagen are currently estimated to become holders of approximately 96% of Signal's outstanding common stock on a fully-diluted basis. The proposed merger remains subject to certain conditions, including approval by Signal's and miRagen's stockholders. The total cash balance of the combined company upon the closing of the proposed merger and the financing is expected to exceed $50 million.